INTRODUCTION

The benefits of antiretroviral therapy (ART) in improving survival, reducing morbidity, and enhancing the quality of life in HIV-infected patients have been widely demonstrated. However, during the early period of immune restoration with ART, immune reconstitution inflammatory syndrome (IRIS) develops in a subset of patients (15–25%). IRIS manifests as clinical deterioration resulting from ART augmented immune responses that cause inflammation in tissues directed at infective, or less frequently, non-infective antigens. The clinical presentation of IRIS varies, with comorbidities associated with it. The etiology of IRIS is unknown but thought to be a reactivation of suppressed immune system after profound suppression by the HIV [1].

IRIS, a life-threatening condition, presents challenges to the clinicians in terms of diagnosis and management as there is lack of proper diagnostic tests and evidence-based guidelines for the management [2,3]. Infective IRIS results from inappropriate or dysregulated immune response directed to pathogen-specific antigens. Essentially, any pathogen that can cause an opportunistic infection, as a result of impaired cellular immune responses can provoke IRIS after pathogen-specific immune responses are restored by ART. Most cases occur within the first 3 months of starting ART, coinciding with a rapid rise in peripheral blood CD4+ cells. Mycobacterial and fungal forms of IRIS usually present with features of T-helper 1 immune response, manifesting with granulomatous inflammation, or suppuration. In contrast, CD8+ T-cells are the dominant inflammatory cells found in IRIS related to viruses [4,5].

To date, no prospective therapeutic trials concerning the management of IRIS have been conducted. All evidence regarding the management of IRIS in the literature relates to case reports and small case series reporting on management practice. Majority of patients with IRIS have a self-limiting disease course. Mortality associated with IRIS is relatively uncommon; however, associated with high morbidity places considerable burden on the healthcare system. Morbidity and mortality rates vary according to the pathogen and organs involved [6,7].

The antimalarial drug hydroxychloroquine (HCQ) is endowed with immune modulatory effects including the reduction of inflammatory cytokine production and of immunoglobulin (IgG) levels, and a down-modulation of natural killer cell activity; these properties have warranted its use in some of the autoimmune conditions [8]. HCQ is used in the treatment of various inflammatory disease conditions, and short-term HCQ is generally well tolerated at a dosage of 400 mg/day. Based on these findings, data exploration was performed from PubMed and Scopus databases using the search terms HCQ, HIV management, and paradoxical tuberculosis (TB)-IRIS. The search conducted did not cite any relevant published literature, where HCQ is tried to treat the HIV patients with TB-IRIS. Hence, this study was conducted to understand the efficacy of short-term HCQ use in the treatment of paradoxical TB-IRIS condition.

METHODS

A prospective uncontrolled longitudinal study was conducted at an HIV care hospital, Mysore, India, between July 2013 and June 2015. The study was approved by the Institutional Ethical Committee of study site hospital. HIV-infected patients who developed paradoxical TB-IRIS during the study were included in the study. The TB-IRIS was defined as per the International Network for the Study of HIV-associated IRIS (INSIH) criteria - (INSIH; World Health Organization; ART) (Table 1). The data regarding the concurrent use of other drugs, laboratory values, opportunistic infections, and other prescribed drugs to any other disease condition were collected from the medical records and treating physician notes. Patients were given with HCQ
A total of 40 patients were included in the study. All patients were given HCQ and followed for the clinical outcomes. The mean age of the patients was found to be 35.87 (±8.54), mean CD4 count was 200 (±263), and mean body mass index was 19.17. The patient’s characteristic is further detailed in Table 2. The ART regimens involved in the study population and the duration of time for the occurrence of IRIS is further detailed in Table 2.

### RESULTS

200 mg/day for a maximum period of 6 months and were followed up at every 15 days for the measurement of treatment outcomes and IRIS progression condition. The data collected were entered into a specially designed excel sheet for easy retrieval of data and analysis. Categorical variables were described using relative frequencies; whereas the standard deviation and mean were used for continuous variables. All analyses were carried out using SPSS software version 21.0.

### DISCUSSION

Data from *in vitro* study, as well as results obtained in the murine model, have shown that HCQ also modulates the intracellular toll-like receptor (TLR) pathway as it also reduces the production of interferon gamma, tumor necrosis factor-α, and interleukin 6. Notably, HCQ decreases Tat-mediated transactivation of HIV-1 TLR in vitro as well—thereby decreasing HIV-1 production and alters the immunogenic properties of gp120 [9]. Based on these findings, the use of HCQ has been evaluated in HIV infection. Results showed that decreases in viral load, IL-6, and serum IgG titers, as well as a reduction of immune activation and a decrease of CD38+CD8+ T-cell and Ki-67 memory CD4+ T-cells can be observed in HIV-infected patients receiving HCQ.

The effect of this compound on these immune parameters is important given the fact that immune activation is believed to play a key role in HIV pathogenesis. This suggestion stems from a number of observations [10]. Thus, the massive destruction of CD4+ T-cells in the gastrointestinal mucosa observed in the initial phases of the infection would provoke severe mucosal alterations. These observations led to therapeutic approaches based either on therapy intensification or immunomodulation that, nevertheless, did not result in any significant effect. Based on these observations and on the ability of HCQ to downregulate TLR-mediated activation, this compound has an effect on immune modulation in HIV-infected IRIS individuals [11].

Systemic corticosteroids or non-steroidal anti-inflammatory agents are used to alleviate the symptoms of IRIS [12,13]. There are no standard guidelines recommending the defined dosage regimen of these agents in the treatment of IRIS. Often, the dosage regimen and choice of anti-inflammatory agents used depends entirely on personal experience of treating physicians. Hence, the therapeutic outcomes are variable. These practices reflect the lack of evidence from controlled trials for the use of anti-inflammatory agents in IRIS [11]. HCQ has established immunomodulatory effects, and due to its relatively low and well-established side effects, the drug may be potentially useful in IRIS patients. However, to rationalize the therapeutic usefulness,

### Table 1: INSHI criteria

| S. No. | Category | Characteristic properties | Total (%) | Recovered |
|--------|----------|--------------------------|-----------|-----------|
| 1      | Age      | <40 years                | 27 (67.5) | 23        |
|        |          | 41–60 years              | 11 (27.5) | 9         |
|        |          | >61 years                | 2 (5)     | 1         |
| 2      | Gender   | Male                     | 31 (77.5) | 11 (27.5) |
|        |          | Female                   | 9 (22.5)  | 2 (5)     |
| 3      | BMI (Kg/m²) | <20                     | 18 (45)   | 6         |
|        |          | 21–25                    | 20 (50)   | 16        |
|        |          | >25                      | 2 (5)     | 1         |
| 4      | CD4 CD4 count (cells/ml) | <200                  | 4 (10)    | 2         |
|        |          | >200                     | 36 (90)   | 31        |
| 5      | Type of TB | TB-lymphadenitis        | 30 (75)   | 25        |
|        |          | Pulmonary-TB             | 6 (15)    | 4         |
|        |          | Abdominal-TB             | 4 (10)    | 4         |

BMI: Body mass index; TB: Tuberculosis

---

**Table 2: Patient characteristics**

| S. No. | Category | Characteristic properties | Total (%) | Recovered |
|--------|----------|--------------------------|-----------|-----------|
| 1 Age  | <40 years | 27 (67.5)                | 23        |
|        | 41–60 years | 11 (27.5)            | 9         |
|        | >61 years  | 2 (5)                   | 1         |
| 2 Gender | Male       | 31 (77.5)               | 11 (27.5) |
|        | Female     | 9 (22.5)                | 2 (5)     |
| 3 BMI (Kg/m²) | <20 | 18 (45)            | 6         |
|        | 21–25      | 20 (50)                 | 16        |
|        | >25        | 2 (5)                   | 1         |
| 4 CD4 CD4 count (cells/ml) | <200 | 4 (10)            | 2         |
|        | >200       | 36 (90)                 | 31        |
| 5 Type of TB | TB-lymphadenitis | 30 (75) | 25        |
|        | Pulmonary-TB | 6 (15)               | 4         |
|        | Abdominal-TB | 4 (10)               | 4         |

ART: Antiretroviral therapy, WHO: World Health Organization

---

**Table 3: INSHI criteria of patients show that patients with**

- One major criterion are 30 (75%),
- One major and one minor are 6 (15%),
- One major and two minor are 2 (5%), and
- Two minor are 2 (5%).

Of these patients, IRIS symptoms improved in 33 patients, and mainly observed as decreased lymphadenopathy (enlarged lymph nodes) among the patients with major criteria and decreased worsening of constitutional symptoms (headache and fever) among the patients with minor criteria with an overall recovery rate of 82.5%.
Table 3: ART regimen responsible for IRIS

| Category                              | Regimen                        | Number of patients (%) |
|---------------------------------------|--------------------------------|------------------------|
| ART regimen                           | Tenofovir+Lamivudine+Elavirenz  | 30 (75)                |
|                                       | Zidovudine+Lamivudine+Elavirenz | 5 (12.5)               |
|                                       | Stavudine+Lamivudine+Elavirenz  | 2 (5)                  |
|                                       | Zidovudine+Lamivudine+Nevirapine| 2 (5)                  |
|                                       | Stavudine+Lamivudine+Atazanavir/Ritonavir | 1 (2.5) |

| Time duration for improvement (weeks) | Number of patients (%) |
|-------------------------------------|------------------------|
| 1–4                                 | 17                     |
| 4–12                                | 11                     |
| 12–24                               | 5                      |

| Time duration between ART initiation and IRIS occurrence (weeks) | Number of patients (%) |
|-----------------------------------------------------------------|------------------------|
| 1–4                                                             | 22 (55)                |
| 4–12                                                            | 13 (32.5)              |
| 12–24                                                           | 5 (12.5)               |

ART: Antiretroviral therapy, IRIS: Immune reconstitution inflammatory syndrome

Further studies are necessary, as there are currently insufficient data to recommend HQ in the management of IRIS.

CONCLUSION

Our observation suggests that prompt recognition of early symptoms of paradoxical TB-IRIS and short-term HQ may be useful in the management of paradoxical TB-IRIS.

AUTHORS CONTRIBUTION

A. Pramod Kumar – Preparation of Manuscript
G. Parthasarathi – Editing of Manuscript
S. N. Mothi, A.P. Sudheer, V.H.T. Swamy, Sri Rama – Collection of Data

CONFLICTS OF INTEREST

None to declare

REFERENCES

1. Suzaan M, Robert J, Dominique J, Graeme M. Management of Patients with Immune Reconstitution Inflammatory Syndrome. Complication of HIV Infection and Treatment Current HIV/AIDS Reports; 2009. p. 171-180.
2. Riddell JT, Daniel RK, Petros CK, Joel EG, Jennifer M, Powel H. Mycobacterium avium complex immune reconstitution inflammatory syndrome: Long term outcomes. J Transl Med 2007;5:50.
3. Swati P, Pankaj K, Vinod R. Bioenhancement effect of piperine and ginger oleo resin on the bioavailability of atazanavir. Int J Pharm Pharm Sci 2015;7:241-5.
4. French MA. HIV/AIDS: Immune reconstitution inflammatory syndrome: A reappraisal. Clin Infect Dis 2009;48:101-7.
5. French MA, Lenzo N, John M, Mallal SA, McKinnon EJ, James IR, et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med 2000;1:107-15.
6. Kumar AP, Prasad SR, Parthasarathi G, Krishna U. Management of immune reconstitution inflammatory syndrome in HIV patients. Int J Univ Pharm Biosci 2016;5:303-11.
7. Kumar AP, Sarathi GP, Sudheer AP, Mothi SN, Swamy VH, Rao S. Incidence and risk factors of renal impairment in HIV-1 infected patients receiving tenofovir based antiretroviral therapy in a South Indian hospital. Int J Pharm Pharm Sci 2017;9:152-5.
8. Karres I, Kremer JP, Dietl I, Steckholzer U, Koch M, Ertel W, et al. Chloroquine inhibits proinflammatory cytokine release into human whole blood. Am J Physiol 1998;274:R1058-64.
9. Sperber K, Kaib TH, Stecher VJ, Banerjee R, Mayer L. Inhibition of human immunodeficiency virus type 1 replication by hydroxychloroquine in T cells and monocytes. AIDS Res Hum Retroviruses 1993;9:91-8.
10. Murray SM, Down CM, Boulware DR, Stauffer WM, Cavert WP, Schacker TW, et al. Reduction of immune activation with chloroquine therapy during chronic HIV infection. J Virol 2010;84:12082-6.
11. Stefania P, Serena P, Giuliano R, Simone P, Roberta T, Barbara A, et al. Hydroxychloroquine drastically reduces immune activation in HIV infected, ART-treated, immunological non responders. Blood J Hematol Lib Org 2014;118:3263-72.
12. Lesko E. Evidence base for using corticosteroids to treat HIV-associated immune reconstitution syndrome. Expert Rev Anti Infect Ther 2006;4:469-78.
13. AIDS Info: Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. Available from: http://www.AIDSinfo.nih.gov.